Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of clinical trials of donanemab and lecanemab for treating Alzheimer's conditions; and whether they plan to provide those drugs through the NHS.

In England, the National Institute for Health and Care Excellence (NICE) is responsible for assessing whether new medicines should be routinely funded by the National Health Service, based on a careful evaluation of clinical and cost effectiveness.

NICE is currently evaluating both lecanemab and donanemab and has not yet published final guidance. NICE was unable to recommend either treatment in its final draft guidance, concluding that the benefits observed in clinical trials, when weighed against the risks and the overall cost, meant they could not currently be considered good value for the NHS. NICE’s independent Appeal Panel has upheld appeals against NICE’s draft recommendations, and its Appraisal Committee will meet to consider the appraisals on 10 June.

The Government has not made a separate assessment of the clinical trials beyond NICE’s independent evaluation.